EN DE
Watch Rafarma Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rafarma Pharmaceuticals Inc (RAFA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Rafarma Pharmaceuticals Inc stock $0.04, price $0.02, upside +156.1%, quality 53 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

RP Rafarma Pharmaceuticals Inc logo Thin data Nov 7, 2026

Rafarma Pharmaceuticals Inc

RAFA · US
Undervalued, but sideways

The stock costs 61% less than our calculation considers fair.

Fair value $0.0384 · Strongly undervalued
Even on cautious assumptions the value is 125% above the price ($0.0338).
Quality 53/100
Mixed Growth (revenue YoY +1.1 %/yr in USD)
Loss over the last twelve months · -87.9% net margin (TTM) · fiscal year 2025 3.8%
Negative free cash flow
Trails peers (3/10)
Narrow moat 19/100 · thin data
Thin data
⚠ Thinly traded
Watch Rafarma Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.42 $0.0140 Fair Value $0.0384 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.0140 – $1.42 · fair‑value band $0.0338 – $0.0430 · the $0.0150 price screens below the $0.0384 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Rafarma Pharmaceuticals in your weekly email

Every Wednesday you see whether Rafarma Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia.

Show moreShow less

It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders.

The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease.

Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia.

As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Stock analysis

Rafarma Pharmaceuticals Inc (RAFA) currently trades at $0.0150, while our model-based Fair Value estimate is $0.0384, implying the stock looks roughly 61% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.1600 per share, and 13 of the 13 models we run sit above the $0.0150 price.

Bear case: the Earnings-Based group reads lowest at $0.0450, and 0 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.0338 (bear) to $0.0430 (bull), the price of $0.0150 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Rafarma Pharmaceuticals Inc reported revenue of $9.2M in FY2025 versus $77.4M in FY2021, a compound −41.3%/yr. Reported net income was $349K in FY2025, compounding −58.3%/yr from FY2021.

Key figures

Market cap $1.8M Micro · P/S ratio 13.2 · EPS (TTM) $−0.0140 · Net margin −87.9% · Return on equity −0.1% · Return on assets (EBIT) 6.8% (5-year average) · Operating margin −81.3% · Free cash flow −$16.0K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 156%, RAFA screens cheaper than that median.

Fair Value models

Bear $0.0338 Fair Value $0.0384 Bull $0.0430
Price $0.0150 · Upside +156.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $0.0900 $0.1600 $0.2600 72
Residual Income $0.0900 $0.0900 $0.0900 71
EPV $0.0500 $0.0500 $0.0600 70
All 14 models by family
DCF Models
Owner Earnings $0.0900 $0.1600 $0.2600 72
Earnings-Based
Graham-Dodd $0.0300 $0.1000 $0.1400 64
Lynch FV $0.0200 $0.0400 $0.0500 60
PEG = 1.0 $0.0200 $0.0400 $0.0500 56
EPV $0.0500 $0.0500 $0.0600 70
Multiples
P/E Multiple $0.0700 $0.0900 $0.1100 63
P/S Multiple $0.0500 $0.0700 $0.0800 58
P/B Multiple n/a n/a $0.0100 51
EV/EBIT $0.0700 $0.1000 $0.1200 63
EV/EBITDA $0.1100 $0.1500 $0.1900 64
EV/Revenue $0.0500 $0.0700 $0.0900 51
Economic Profit
Residual Income $0.0900 $0.0900 $0.0900 71
ROIC Compounder $0.0500 $0.0500 $0.0600 70
Growth Earnings
Growth-Adj P/E $0.0500 $0.0700 $0.0900 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−50.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−50.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 5%
⚠ Revenue per share shrinking 3.9%/yr over ~18Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Watch RAFA, get fair value alerts →

Compare Rafarma Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside +156.0% · Top 25%
Profitability
Return on assets 2.9% · Below median
Net margin (12 months) −87.9% · Bottom 25%
Operating margin (12 months) −81.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.17× · Cheapest 25%
P/S (12 months) 13.17× · Priciest 25%
EV/EBITDA 3.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs RAFA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs RAFA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs RAFA
Haleon plc HLN $9.14 $8.61 −6% vs RAFA
Merck KGaA MRK €148.75 €109.18 −27% vs RAFA
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs RAFA
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs RAFA
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs RAFA
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs RAFA
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs RAFA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rafarma Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rafarma Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/RAFA

Frequently asked questions

Is Rafarma Pharmaceuticals Inc (RAFA) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.0384 versus a price of $0.0150, about +156% upside (undervalued).
What is the fair value of RAFA?
Our model-based fair value for Rafarma Pharmaceuticals Inc is $0.0384 (as of Nov 7, 2026), built from audited fundamentals. The current price: $0.0150.
What is the quality score of RAFA?
Rafarma Pharmaceuticals Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rafarma Pharmaceuticals Inc (RAFA)?
Our model-based price target is the fair value of $0.0384 (as of Nov 7, 2026) from 14 valuation models. Cautious scenario $0.0338, optimistic scenario $0.0430. It is a calculation from audited fundamentals, not an analyst target.
What is the Rafarma Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.0384, about +156% upside versus a price of $0.0150 (undervalued). Cautious scenario $0.0338, optimistic scenario $0.0430. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Rafarma Pharmaceuticals Inc (RAFA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rafarma Pharmaceuticals Inc it is $0.0384 per share (as of Nov 7, 2026), against a price of $0.0150. It is the blended result of 14 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Economic Profit, Growth Earnings).
Is Rafarma Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, RAFA trades below its calculated fair value: price $0.0150, fair value $0.0384, a gap of about +156% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RAFA?
No. The price is what the market pays today ($0.0150); the fair value is what the company's own numbers justify ($0.0384). For Rafarma Pharmaceuticals Inc the two are $0.0234 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rafarma Pharmaceuticals Inc worth?
The market values Rafarma Pharmaceuticals Inc at about $1.8M (market capitalisation, as of Nov 7, 2026). Per share that is $0.0150; our models calculate a fair value of $0.0384 per share.
What do the bullish and bearish scenarios say about RAFA?
Our models span a range for Rafarma Pharmaceuticals Inc: cautious scenario $0.0338, base $0.0384, optimistic $0.0430 per share (as of Nov 7, 2026, price $0.0150). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rafarma Pharmaceuticals Inc (RAFA)?
Balance-sheet figures for Rafarma Pharmaceuticals Inc (as of Nov 7, 2026): return on equity −0.1%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is RAFA from its 52-week high?
Rafarma Pharmaceuticals Inc trades at $0.0150, about 83% below its 52-week high of $0.0890 and 7% above the low of $0.0140 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0384 is for.
Which stocks are comparable to Rafarma Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rafarma Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $0.0150, calculated fair value $0.0384 (+156%), Quality Score 53/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RAFA calculated?
We run Rafarma Pharmaceuticals Inc through 14 models from 5 families: DCF Models, Earnings-Based, Multiples, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.0384 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Rafarma Pharmaceuticals Inc currently trades 61% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rafarma Pharmaceuticals Inc (RAFA)?
The closing price on Nov 6, 2026 was $0.0150. Our model-based fair value is $0.0384, about +156% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rafarma Pharmaceuticals Inc right now?
The price is below even our cautious bear case ($0.0338). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Rafarma Pharmaceuticals Inc

How large is the market capitalisation of Rafarma Pharmaceuticals Inc (RAFA)?
The market capitalisation of Rafarma Pharmaceuticals Inc is $1.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rafarma Pharmaceuticals Inc (RAFA)?
The price-to-sales ratio of Rafarma Pharmaceuticals Inc is 13.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rafarma Pharmaceuticals Inc (RAFA)?
Earnings per share at Rafarma Pharmaceuticals Inc are $−0.0140. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rafarma Pharmaceuticals Inc (RAFA)?
The net margin of Rafarma Pharmaceuticals Inc is −87.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rafarma Pharmaceuticals Inc (RAFA)?
The return on equity (ROE) of Rafarma Pharmaceuticals Inc is −0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rafarma Pharmaceuticals Inc (RAFA)?
On an EBIT basis the return on assets of Rafarma Pharmaceuticals Inc is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rafarma Pharmaceuticals Inc (RAFA)?
The operating margin of Rafarma Pharmaceuticals Inc is −81.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Rafarma Pharmaceuticals Inc (RAFA) generate?
The free cash flow of Rafarma Pharmaceuticals Inc is −$16.0K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rafarma Pharmaceuticals Inc (RAFA) hold?
Rafarma Pharmaceuticals Inc holds more cash than debt, $35.0K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Rafarma Pharmaceuticals Inc in the live analysis

One click puts Rafarma Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.